Correlation Between Viridian Therapeutics and Cocrystal Pharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Viridian Therapeutics and Cocrystal Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Viridian Therapeutics and Cocrystal Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Viridian Therapeutics and Cocrystal Pharma, you can compare the effects of market volatilities on Viridian Therapeutics and Cocrystal Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Viridian Therapeutics with a short position of Cocrystal Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Viridian Therapeutics and Cocrystal Pharma.

Diversification Opportunities for Viridian Therapeutics and Cocrystal Pharma

-0.63
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Viridian and Cocrystal is -0.63. Overlapping area represents the amount of risk that can be diversified away by holding Viridian Therapeutics and Cocrystal Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cocrystal Pharma and Viridian Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Viridian Therapeutics are associated (or correlated) with Cocrystal Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cocrystal Pharma has no effect on the direction of Viridian Therapeutics i.e., Viridian Therapeutics and Cocrystal Pharma go up and down completely randomly.

Pair Corralation between Viridian Therapeutics and Cocrystal Pharma

Given the investment horizon of 90 days Viridian Therapeutics is expected to under-perform the Cocrystal Pharma. But the stock apears to be less risky and, when comparing its historical volatility, Viridian Therapeutics is 1.12 times less risky than Cocrystal Pharma. The stock trades about -0.21 of its potential returns per unit of risk. The Cocrystal Pharma is currently generating about 0.18 of returns per unit of risk over similar time horizon. If you would invest  146.00  in Cocrystal Pharma on February 28, 2024 and sell it today you would earn a total of  74.00  from holding Cocrystal Pharma or generate 50.68% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Viridian Therapeutics  vs.  Cocrystal Pharma

 Performance 
       Timeline  
Viridian Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Viridian Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental indicators remain very healthy which may send shares a bit higher in June 2024. The recent disarray may also be a sign of long period up-swing for the firm investors.
Cocrystal Pharma 

Risk-Adjusted Performance

14 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Cocrystal Pharma are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. Even with relatively unfluctuating fundamental indicators, Cocrystal Pharma reported solid returns over the last few months and may actually be approaching a breakup point.

Viridian Therapeutics and Cocrystal Pharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Viridian Therapeutics and Cocrystal Pharma

The main advantage of trading using opposite Viridian Therapeutics and Cocrystal Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Viridian Therapeutics position performs unexpectedly, Cocrystal Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cocrystal Pharma will offset losses from the drop in Cocrystal Pharma's long position.
The idea behind Viridian Therapeutics and Cocrystal Pharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

Other Complementary Tools

Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine